Potential conflict of interest: J.G. has consulted for Gilead; A.S.P. has received research grants from Novartis and Roche and has consulted for Merck, Gilead, Achillion, Bristol-Myers Squibb, Progenics, and Santaris Pharmaceuticals; S.K. was employed by Novartis when this work was done (currently at the Bill and Melinda Gates Foundation); and J.Y., M.L., B.L., and N.V.N. are Novartis employees.
Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients
Version of Record online: 1 APR 2014
© 2014 by the American Association for the Study of Liver Diseases. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Volume 59, Issue 5, pages 1706–1714, May 2014
How to Cite
Guedj, J., Yu, J., Levi, M., Li, B., Kern, S., Naoumov, N. V. and Perelson, A. S. (2014), Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients. Hepatology, 59: 1706–1714. doi: 10.1002/hep.26989
- Issue online: 23 APR 2014
- Version of Record online: 1 APR 2014
- Accepted manuscript online: 23 DEC 2013 03:36AM EST
- Manuscript Accepted: 19 DEC 2013
- Manuscript Received: 13 JUL 2013
Additional Supporting Information may be found in the online version of this article at the publisher's website.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.